AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17984150 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased-intensity physical activity
Number of subjects: 29
Study 17984150 — intervention group
Group type: COMPARATOR
Intervention: Social activity
Number of subjects: 29
Study 16416004 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha alone for 1 month followed by 5 months of continuous treatment with interferon-alpha (treatment group A)
Number of subjects: 66
Study 16416004 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha combined with thymosin-alpha1 for 1 month followed by 5 months of continuous treatment with interferon-alpha and thymosin-alpha1 (treatment group B)
Number of subjects: 66
Study 16416004 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antiviral drug after lamivudine withdrawal)
Number of subjects: 66
Study 16416004 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha alone or combined with thymosin-alpha1
Number of subjects: 66
Study 12432287 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback intervention
Number of subjects: 118
Study 10461814 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 21
Study 10461814 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 21
Study 10461814 — intervention group
Group type: COMPARATOR
Intervention: Coordination training
Number of subjects: 21
Study 7554545 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (5 mg)
Number of subjects: 17
Study 7554545 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril (20 mg)
Number of subjects: 17
Study 1685651 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone-treated blood
Number of subjects: 10
Study 1685651 — intervention group
Group type: COMPARATOR
Intervention: Unprocessed blood (Control)
Number of subjects: 10
Study 7469773 — intervention group
Group type: EXPERIMENTAL
Intervention: Open abdominal paracentesis and lavage
Number of subjects: 210
Study 7469773 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous abdominal paracentesis and lavage
Number of subjects: 210
Study 31177984 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalamic location of intracerebral hemorrhage
Number of subjects: 467
Study 31177984 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior limb internal capsule involvement
Number of subjects: 467
Study 31177984 — intervention group
Group type: EXPERIMENTAL
Intervention: Globus pallidus/putamen involvement
Number of subjects: 467
Study 31177984 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior limb internal capsule involvement
Number of subjects: 467
Study 31177984 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudate location
Number of subjects: 467
Study 31177984 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior limb internal capsule lesions
Number of subjects: 467
Study 27914817 — intervention group
Group type: EXPERIMENTAL
Intervention: Controller medicine
Number of subjects: 175
Study 27914817 — intervention group
Group type: EXPERIMENTAL
Intervention: Quick relief medicine
Number of subjects: 175
Study 27914817 — intervention group
Group type: EXPERIMENTAL
Intervention: Spacer
Number of subjects: 175
Study 27914817 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental help with medications
Number of subjects: 175
Study 27914817 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaler technique
Number of subjects: 175
Study 27914817 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of medications
Number of subjects: 175
Study 26435363 — intervention group
Group type: EXPERIMENTAL
Intervention: Daylight photodynamic therapy (DL‐PDT) with methyl aminolevulinate (MAL)
Number of subjects: 100
Study 26435363 — intervention group
Group type: COMPARATOR
Intervention: Conventional photodynamic therapy (c‐PDT) with methyl aminolevulinate (MAL)
Number of subjects: 100
Study 26435363 — intervention group
Group type: EXPERIMENTAL
Intervention: Daylight photodynamic therapy (DL‐PDT)
Number of subjects: 100
Study 26435363 — intervention group
Group type: COMPARATOR
Intervention: Conventional photodynamic therapy (c‐PDT)
Number of subjects: 100
Study 23230105 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-11 Synch (MGA)
Number of subjects: 477
Study 23230105 — intervention group
Group type: COMPARATOR
Intervention: 7-11 CIDR
Number of subjects: 477
Study 23230105 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-11 Synch (with GnRH)
Number of subjects: 477
Study 23230105 — intervention group
Group type: COMPARATOR
Intervention: 7 Synch (without GnRH)
Number of subjects: 477
Study 21862727 — intervention group
Group type: EXPERIMENTAL
Intervention: R-leg (exercise with restricted blood flow)
Number of subjects: 2
Study 21862727 — intervention group
Group type: COMPARATOR
Intervention: NR-leg (exercise with normal blood flow)
Number of subjects: 2
Study 21862727 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultured human myotubes with AICAR stimulation
Number of subjects: 2
Study 21862727 — intervention group
Group type: EXPERIMENTAL
Intervention: AICAR combined with norepinephrine
Number of subjects: 2
Study 19608845 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection (Group S): 30 mL of mepivacaine 1.5% injected posterior to the axillary artery
Number of subjects: 100
Study 19608845 — intervention group
Group type: COMPARATOR
Intervention: Triple injections (Group T): 10 mL of mepivacaine 1.5% injected on the posterior, medial, and lateral aspects of the axillary artery
Number of subjects: 100
Study 16448828 — intervention group
Group type: EXPERIMENTAL
Intervention: TTM-based counselling in physiotherapy (10 min counselling prior to each of 10 sessions of physiotherapy)
Number of subjects: 170
Study 16448828 — intervention group
Group type: COMPARATOR
Intervention: Placebo ultrasound treatment (inactivated device, 10 sessions of physiotherapy of 20 min each)
Number of subjects: 170
Study 15459167 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 (group A)
Number of subjects: 74
Study 15459167 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (group B)
Number of subjects: 74
Study 12861170 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ECV (34-36 weeks gestation)
Number of subjects: 233
Study 12861170 — intervention group
Group type: COMPARATOR
Intervention: Delayed ECV (37-38 weeks gestation)
Number of subjects: 233
Study 9928781 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain diary intervention
Number of subjects: 159
Study 7560617 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril therapy
Number of subjects: 0
Study 2286709 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (fixed doses to achieve plasma levels above and below 18 ng/ml)
Number of subjects: 25
Study 7028259 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate CAMP (cyclophosphamide, doxorubicin, methotrexate, and procarbazine)
Number of subjects: 72
Study 7028259 — intervention group
Group type: COMPARATOR
Intervention: Initial low-dose single-agent CCNU (CAMP postponed)
Number of subjects: 72
Study 7028259 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate CAMP
Number of subjects: 72
Study 7028259 — intervention group
Group type: COMPARATOR
Intervention: Postponed CAMP
Number of subjects: 72
Study 7028259 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life measures
Number of subjects: 72
Study 31998998 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentration of Benefit index (Cb)
Number of subjects: 0
Study 31998998 — intervention group
Group type: EXPERIMENTAL
Intervention: Expected treatment outcomes with knowledge of covariates
Number of subjects: 0
Study 31998998 — intervention group
Group type: EXPERIMENTAL
Intervention: Parametric and semiparametric estimators
Number of subjects: 0
Study 30176834 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min vigorous-intensity aerobic exercise session 24 hours prior to each anthracycline treatment
Number of subjects: 56
Study 30176834 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepared diet reduced to 50% of caloric needs for 48 hours prior to each anthracycline treatment
Number of subjects: 56
Study 30176834 — intervention group
Group type: COMPARATOR
Intervention: Usual cancer care
Number of subjects: 56
Study 28139564 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib
Number of subjects: 40
Study 28139564 — intervention group
Group type: COMPARATOR
Intervention: Meloxicam
Number of subjects: 40
Study 24508349 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated glucose (>7.8 mmol/L)
Number of subjects: 3383
Study 22420417 — intervention group
Group type: EXPERIMENTAL
Intervention: SoS letter only
Number of subjects: 139356
Study 22420417 — intervention group
Group type: EXPERIMENTAL
Intervention: SoS letter and SoS brochure
Number of subjects: 139356
Study 22420417 — intervention group
Group type: COMPARATOR
Intervention: SoS brochure only
Number of subjects: 139356
Study 19947986 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased nocturnal oxygen flow rate (1 L more oxygen)
Number of subjects: 38
Study 19947986 — intervention group
Group type: COMPARATOR
Intervention: Daytime oxygen flow rate
Number of subjects: 38
Study 18762517 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study 18762517 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling treatment
Number of subjects: 0
Study 16046725 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron intervention (specifics not provided)
Number of subjects: 9
Study 12035957 — intervention group
Group type: EXPERIMENTAL
Intervention: 30mg ketorolac
Number of subjects: 65
Study 12035957 — intervention group
Group type: COMPARATOR
Intervention: Standard anaesthetic and surgical technique
Number of subjects: 65
Study 10901709 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifetroban (3 mg/kg in rats)
Number of subjects: 4
Study 10901709 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifetroban (1 mg/kg in dogs)
Number of subjects: 4
Study 10901709 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifetroban (1 mg/kg in monkeys)
Number of subjects: 4
Study 10901709 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifetroban (50 mg in humans)
Number of subjects: 4
Study 8890312 — intervention group
Group type: EXPERIMENTAL
Intervention: Teeth clenching
Number of subjects: 0
Study 1900663 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin and doxycycline
Number of subjects: 148
Study 1900663 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin and tobramycin
Number of subjects: 148
Study 1900663 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 148
Study 6830051 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 ppm sulfur dioxide (SO2)
Number of subjects: 23
Study 6830051 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 ppm sulfur dioxide (SO2)
Number of subjects: 23
Study 6830051 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 ppm sulfur dioxide (SO2)
Number of subjects: 23
Study 6830051 — intervention group
Group type: COMPARATOR
Intervention: Control (0 ppm sulfur dioxide)
Number of subjects: 23
Study 31465443 — intervention group
Group type: EXPERIMENTAL
Intervention: Affect Regulation Training (ART)
Number of subjects: 218
Study 31465443 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control (WLC)
Number of subjects: 218
Study 31465443 — intervention group
Group type: COMPARATOR
Intervention: Condition controlling for common factors (CFC)
Number of subjects: 218
Study 29499343 — intervention group
Group type: EXPERIMENTAL
Intervention: Probabilistic Food Choice Questionnaire (PFCQ)
Number of subjects: 110
Study 29499343 — intervention group
Group type: EXPERIMENTAL
Intervention: Probabilistic Monetary Choice Questionnaire (PMCQ)
Number of subjects: 110
Study 29499343 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay discounting (DD) tasks
Number of subjects: 110
Study 25953002 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 48
Study 25953002 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D mChoi criteria
Number of subjects: 48
Study 25953002 — intervention group
Group type: COMPARATOR
Intervention: 2D or 3D imaging criteria
Number of subjects: 48
Study 24674976 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic training (FIO2 = 0.15)
Number of subjects: 17
Study 24674976 — intervention group
Group type: COMPARATOR
Intervention: Normoxic training (placebo)
Number of subjects: 17
Study 21362642 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive journaling
Number of subjects: 183
Study 21362642 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 183
Study 20361918 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (n = 104)
Number of subjects: 198
Study 18455841 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 rgp160
Number of subjects: 12
Study 18455841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15970392 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupported dieting
Number of subjects: 3
Study 15970392 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dieting groups
Number of subjects: 3
Study 15970392 — intervention group
Group type: COMPARATOR
Intervention: Commercially available weight loss group
Number of subjects: 3
Study 15970392 — intervention group
Group type: COMPARATOR
Intervention: Non-dieting controls
Number of subjects: 3
Study 12186623 — intervention group
Group type: EXPERIMENTAL
Intervention: One-week quadruple therapy (bismuth-based triple therapy plus a PPI or histamine receptor 2-blocker)
Number of subjects: 0
Study 12186623 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone-based triple therapy (furazolidone plus an antibiotic and a bismuth salt, a PPI or RBC)
Number of subjects: 0
Study 12186623 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolone-based triple therapy (levofloxacin or moxifloxacin plus an antibiotic and a PPI)
Number of subjects: 0
Study 12186623 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecabet sodium-based triple therapy (ecabet plus two antibiotics)
Number of subjects: 0
Study 12186623 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin in combination with a PPI and amoxycillin
Number of subjects: 0
Study 16021868 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine-containing regimen
Number of subjects: 57
Study 16021868 — intervention group
Group type: COMPARATOR
Intervention: Protease inhibitor (PI) regimen
Number of subjects: 57
Study 8924308 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide with EMLA cream
Number of subjects: 60
Study 8924308 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide with intradermal lidocaine
Number of subjects: 60
Study 8924308 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide alone
Number of subjects: 60
Study 7523772 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 5 mg b.i.d.
Number of subjects: 693
Study 7523772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 693
Study 3499015 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccinated children
Number of subjects: 1421
Study 3499015 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated children
Number of subjects: 1421
Study 3499015 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 1421
Study 3499015 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculin testing in vaccinated children
Number of subjects: 1421
Study 30195044 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFJ morphological parameters (S, Sτ, Sφ)
Number of subjects: 408
Study 30195044 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFJ morphological parameters (S, Sτ)
Number of subjects: 408
Study 30195044 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFJ morphological parameters (S, Sτ, Sυ)
Number of subjects: 408
Study 26984864 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid status telemedicine alerts (intervention arm)
Number of subjects: 1002
Study 26984864 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control arm)
Number of subjects: 1002
Study 25273893 — intervention group
Group type: EXPERIMENTAL
Intervention: Active T-PEMF (one daily dose)
Number of subjects: 65
Study 25273893 — intervention group
Group type: EXPERIMENTAL
Intervention: Active T-PEMF (two daily doses)
Number of subjects: 65
Study 25273893 — intervention group
Group type: COMPARATOR
Intervention: Placebo T-PEMF (one daily dose)
Number of subjects: 65
Study 24384592 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral tenofovir (TDF) and emtricitabine/tenofovir (FTC/TDF) PrEP
Number of subjects: 0
Study 24384592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21451938 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg)
Number of subjects: 21
Study 21451938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 19936518 — intervention group
Group type: EXPERIMENTAL
Intervention: Wand computer-controlled local anesthesia application
Number of subjects: 16
Study 19936518 — intervention group
Group type: COMPARATOR
Intervention: Conventional anesthesia technique
Number of subjects: 16
Study 17014550 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume haemofiltration (HVHF) at 6 L/h
Number of subjects: 33
Study 17014550 — intervention group
Group type: COMPARATOR
Intervention: Continuous venovenous haemofiltration (CVVH) at 2 L/h
Number of subjects: 33
Study 15257738 — intervention group
Group type: EXPERIMENTAL
Intervention: High brushing force (+/‐3.5 N)
Number of subjects: 35
Study 15257738 — intervention group
Group type: EXPERIMENTAL
Intervention: Low brushing force (+/‐1.5 N)
Number of subjects: 35
Study 15257738 — intervention group
Group type: COMPARATOR
Intervention: Control (Low brushing force)
Number of subjects: 35
Study 11020900 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabexate mesilate infusion at a dose of 100 mg/hr for 7 days
Number of subjects: 52
Study 9540058 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tamoxifen (TAM) at doses of 40, 80 or 120 mg/day
Number of subjects: 40
Study 9540058 — intervention group
Group type: COMPARATOR
Intervention: Surgery, radiotherapy (4500-6000 cGy), and carboplatin (CBDCA; dose of 450-600 mg/m2)
Number of subjects: 40
Study 7800587 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (12 grams daily, 3.6 g of EPA and DHA) for 3 weeks
Number of subjects: 20
Study 7800587 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (12 grams daily) for 3 weeks
Number of subjects: 20
Study 7800587 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (12 grams daily) for 6 weeks (in 9 patients)
Number of subjects: 20
Study 3388151 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (DTZ) 90 mg twice daily, increased to 180 mg if non-responders after 8 weeks
Number of subjects: 29
Study 3388151 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCT) 25 mg once daily, increased to 50 mg if non-responders after 8 weeks
Number of subjects: 29
Study 29311135 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐823778 (single and multiple ascending doses)
Number of subjects: 0
Study 29311135 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐823778 in poor metabolizers (PMs) of CYP2C19
Number of subjects: 0
Study 29311135 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐823778 in subjects with predicted CYP2C19 PM phenotype
Number of subjects: 0
Study 29311135 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐823778 (overall safety profile)
Number of subjects: 0
Study 29311135 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐823778 (pharmacokinetics)
Number of subjects: 0
Study 26805006 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP with aPDT
Number of subjects: 90
Study 26805006 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 90
Study 25272034 — intervention group
Group type: EXPERIMENTAL
Intervention: Pylorus removal during subtotal stomach-preserving pancreaticoduodenectomy or pylorus-resecting pancreaticoduodenectomy
Number of subjects: 2599
Study 25272034 — intervention group
Group type: EXPERIMENTAL
Intervention: Pylorus removal
Number of subjects: 2599
Study 25272034 — intervention group
Group type: COMPARATOR
Intervention: Pylorus-preserving group
Number of subjects: 2599
Study 22723267 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone (RSG) 4 mg b.i.d
Number of subjects: 28
Study 22723267 — intervention group
Group type: COMPARATOR
Intervention: matching placebo (PLC)
Number of subjects: 28
Study 20402570 — intervention group
Group type: EXPERIMENTAL
Intervention: Odor identification ability measured by the University of Pennsylvania Smell Identification Test (SIT) during 24 hr of sleep deprivation
Number of subjects: 54
Study 20402570 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance on the Wisconsin Card Sorting Test (WCST) following 45 hr of wakefulness
Number of subjects: 54
Study 18326617 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium- and vitamin D3-fortified milk
Number of subjects: 109
Study 18326617 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fortified milk provided)
Number of subjects: 109
Study 16122470 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic CPB (28 degrees C)
Number of subjects: 59
Study 16122470 — intervention group
Group type: COMPARATOR
Intervention: Normothermic CPB (35‐37 degrees C)
Number of subjects: 59
Study 16122470 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 59
Study 12462697 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume fiber-reinforced composite substructure
Number of subjects: 39
Study 12462697 — intervention group
Group type: COMPARATOR
Intervention: Low-volume fiber-reinforced composite substructure
Number of subjects: 39
Study 12462697 — intervention group
Group type: EXPERIMENTAL
Intervention: All surviving prostheses
Number of subjects: 39
Study 10204379 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatments in addition to non-steroidal anti-inflammatory drugs and intraarticular administration of glucocorticosteroids and inhibitors of proteases
Number of subjects: 40
Study 10204379 — intervention group
Group type: COMPARATOR
Intervention: Non-steroidal anti-inflammatory drugs together with intraarticular administration of glucocorticosteroids and inhibitors of proteases
Number of subjects: 40
Study 2569279 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms/kg vecuronium bromide
Number of subjects: 40
Study 2569279 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms/kg vecuronium bromide
Number of subjects: 40
Study 2569279 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 micrograms/kg vecuronium bromide
Number of subjects: 40